Relapse and overall survival by TCR status or genotype
. | Cumulative incidence of relapse, 4-y estimates, % (95% CI) . | Overall survival, 4-y estimates, % (95% CI) . |
|---|---|---|
| All patients | 60 (50-71) | 44 (33-54) |
| TCR subsets | ||
| Immature | 56 (36-76) | 30 (14-49) |
| Pre-αβ | 59 (42-77) | 59* (38-75) |
| TCR+ | 66 (49-82) | 30 (14-48) |
| Genotype subsets | ||
| CALM-AF10 | 57 (27-90) | 42 (6-77) |
| SIL-TAL1 | 82† (56-97) | 45 (17-71) |
| HOX11 | 45 (22-77) | 56 (20-80) |
| HOX11L2 | 83† (48-99) | 11‡ (1-40) |
| Others | 55 (39-71) | 45 (28-61) |
| TAL1 | 62 (42-82) | 39 (18-60) |
| LYL | NE | NE |
| LMO2 | 68 (42-85) | 29 (8-55) |
. | Cumulative incidence of relapse, 4-y estimates, % (95% CI) . | Overall survival, 4-y estimates, % (95% CI) . |
|---|---|---|
| All patients | 60 (50-71) | 44 (33-54) |
| TCR subsets | ||
| Immature | 56 (36-76) | 30 (14-49) |
| Pre-αβ | 59 (42-77) | 59* (38-75) |
| TCR+ | 66 (49-82) | 30 (14-48) |
| Genotype subsets | ||
| CALM-AF10 | 57 (27-90) | 42 (6-77) |
| SIL-TAL1 | 82† (56-97) | 45 (17-71) |
| HOX11 | 45 (22-77) | 56 (20-80) |
| HOX11L2 | 83† (48-99) | 11‡ (1-40) |
| Others | 55 (39-71) | 45 (28-61) |
| TAL1 | 62 (42-82) | 39 (18-60) |
| LYL | NE | NE |
| LMO2 | 68 (42-85) | 29 (8-55) |